ProEncia Advances Novel Periodontal Disease Treatments
Fast-growth biopharma startup develops groundbreaking product pipeline to target oral health epidemic. Twin Cities-based ProEncia Biotechnology, a biopharma startup, today announced the company has closed significant pre-seed funding to advance its next-generation periodontal disease treatment. Funding will be applied to further develop, commercialize, and license a pipeline of novel, non-invasive periodontal care products designed for patients suffering from periodontal disease at all stages of severity. “According to the World Health Organization, more than one billion people globally, and more than 100 million people in the U.S., suffer from periodontal disease,” said Tapos Ghosh, CEO and Co-Founder of ProEncia Biotechnology. “There’s an urgent need for innovation to resolve this epidemic and bring safe, effective solutions to lifelong sufferers of this condition.” ProEncia also announced that it had received official confirmation from the United Stat...
